Neal Shore and Evan Yu share in a discussion on the evolving role of PARP inhibitors in the treatment of mCRPC.  Dr. Yu reviews the early interim results of rucaparib in the TRITON-2 study and points out the intricacies that must be considered when evaluating all the recent data involving DNA mutations. Drs. Shore and Yu discuss the class of  PARP inhibitors in clinical development and what makes each of these agents unique.  Dr. Yu points out that all the data needs to be interpreted carefully since not all trials are using a standardized assay for each of the genetic mutations making cross comparisons between trials challenging. 

Biographies:

Evan Yu, MD a medical oncologist and Professor, Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, UW Medicine

Neal Shore, MD, FACS is the Medical Director of the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. He serves on several industry advisory boards as well as academic and advocacy networks: including the Society Urologic Oncology Clinical Trials Consortium, Bladder Cancer Advocacy Network, and the Large Urology Group Practice Association.